CRISPR Therapeutics (CRSP) Financial Analysis & Valuation | Quarter Chart
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allo... more
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serio... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $4.78B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CH | CEO | Samarth Kulkarni |
| IPO Date | 2016-10-19 | CAGR | — |
| Employees | 393 | Website | www.crisprtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRSP chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $5.41B | P/E | -10.38 | Forward P/E | -13.9 | PEG | — |
| P/S | 1542.32 | P/B | 11.74 | P/CF | -55.95 | P/FCF | -55.59 |
| Sales | $13.39M | Sales 1Y | -64.15% | Sales 3Y | -92.13% | Sales 5Y | -98.51% |
| EPS | $-4.76 | EPS 1Y | -12.34% | EPS 3Y | -10.19% | EPS 5Y | -193.7% |
| Sales QoQ | 598.29% | EPS QoQ | -26.56% | Sales QoQ Avg | 165.97% | EPS QoQ Avg | -16.82% |
| Gross Margin | -1220.03% | Operating Margin | -3989.99% | Profit Margin | -3368.72% | ROCE | -21.22% |
| ROA | -17% | ROE | -24% | Altman Z Score | 2.23 | Piotroski Score | 3 |
| Current Ratio | 17.85 | Quick Ratio | 17.85 | Cash Ratio | 2.19 | Op. CF Ratio | -0.63 |
| Debt/Equity | 0.45 | Debt/Assets | 0.3 | Lt Debt/Equity | 0.44 | Lt Debt/Cap. | 0.3 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $5.41B | P/E Ratio | -10.38 |
| Forward P/E | -13.9 | PEG Ratio | — |
| P/S Ratio | 1542.32 | P/B Ratio | 11.74 |
| P/CF Ratio | -55.95 | P/FCF Ratio | -55.59 |
| EPS | $-4.76 | EPS Growth 1Y | -12.34% |
| EPS Growth 3Y | -10.19% | EPS Growth 5Y | -193.7% |
| Revenue Growth 1Y | -64.15% | Gross Margin | -1220.03% |
| Operating Margin | -3989.99% | Profit Margin | -3368.72% |
| ROE | -24% | ROA | -17% |
| ROCE | -21.22% | Current Ratio | 17.85 |
| Quick Ratio | 17.85 | Cash Ratio | 2.19 |
| Debt/Equity | 0.45 | Interest Coverage | — |
| Altman Z Score | 2.23 | Piotroski Score | 3 |
CRISPR Therapeutics (CRSP) valuation & financials
CRISPR Therapeutics (CRSP) has a market capitalization of $4.78B and trades at a price-to-earnings ratio of -10.4. It operates in the Healthcare sector (Biotechnology).
CRISPR Therapeutics's revenue grew -64.2% over the last year.
CRISPR Therapeutics's next earnings report is scheduled for November 9, 2026 (provider scheduled date); analysts estimate EPS of $-1.04. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)